인벤티지랩
Financials
Valuation Metrics
인벤티지랩's Market Cap is ₩4165B. At end of 2025 it was ₩1.1T. Ranked #500 of 2,436 in KR market (top 21%), #190 of 1,649 on KOSDAQ (top 12%), #58 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 416.53B KRW | KR#500/2,436 Sec#58/234 |
| Revenue | 3.16B KRW | KR#2,373/2,436 Sec#207/234 |
| Net Income | -6.83B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 214.77B KRW | KR#1,237/2,436 Sec#91/234 |
| Net Assets | 115.04B KRW | KR#1,297/2,436 Sec#104/234 |
| Employees | 69 | KR#1,867/2,436 Sec#160/234 |
| Value | ||
| P/B | 3.62x | KR#2,171/2,436 Sec#174/234 |
| P/S | 131.71x | KR#2,397/2,436 Sec#216/234 |
| FCF Yield | -6.22% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -5.93% | KR#1,777/2,436 Sec#131/234 |
| ROA | -3.18% | KR#1,779/2,436 Sec#132/234 |
| Op. Margin | -992.67% | KR#2,388/2,436 Sec#216/234 |
| Revenue Growth | 132.26% | KR#109/2,436 Sec#18/234 |
| Financial Health | ||
| Debt Ratio | 186.70% | KR#1,593/2,436 Sec#182/234 |
| Total Debt | 28.21B KRW | KR#1,229/2,436 Sec#99/234 |
| FCF | -25.89B KRW | KR#1,962/2,436 Sec#189/234 |
| Cash | 107.12B KRW | KR#445/2,436 Sec#22/234 |
| Current Ratio | 2.34x | KR#802/2,436 Sec#97/234 |
| Performance | ||
| 1Y Return | 2.12% | KR#672/2,436 Sec#49/234 |
| 1M Return | -17.85% | KR#2,118/2,436 Sec#212/234 |
| From 52W High | -69.22% | KR#2,103/2,436 Sec#187/234 |
| 1Y MDD | -75.13% | KR#2,147/2,436 Sec#191/234 |
| Trading | ||
| Volume | 65,269 shares | KR#1,195/2,436 Sec#118/234 |
| Foreign Own. | 12.35% | KR#398/2,436 Sec#35/234 |
| Per Share | ||
| EPS | 225 KRW | KR#1,174/2,436 Sec#81/234 |
| BPS | 6,527 KRW | KR#1,244/2,436 Sec#87/234 |
Company Info
Inventis Lab was established in 2015, and in 2025, it acquired KOSDAQ-listed Curatis, securing a mass production base for long-acting injectable drugs and gene therapy/mRNA vaccines. It possesses an IVL platform that applies microfluidic technology to drug research and development, providing long-acting injectable drug development and LNP manufacturing services. The company has license agreements with domestic and international pharmaceutical companies and is expanding clinical trial material production and CDMO business through manufacturing facilities in Curatis' GMP factory. Inventis Lab is headquartered in Seongnam-si, Gyeonggi-do.